30-day FRN

Federal Register / Vol. 85, No. 12 / Friday, January 17, 2020 / Notices
2020 POVERTY GUIDELINES FOR
ALASKA—Continued
Poverty
guideline

Persons in family/household
6 ..................................................
7 ..................................................
8 ..................................................

43,950
49,550
55,150

For families/households with more
than 8 persons, add $5,600 for each
additional person.

2020 POVERTY GUIDELINES FOR
HAWAII
Poverty
guideline

Persons in family/household

lotter on DSKBCFDHB2PROD with NOTICES

1
2
3
4
5
6
7
8

..................................................
..................................................
..................................................
..................................................
..................................................
..................................................
..................................................
..................................................

$14,680
19,830
24,980
30,130
35,280
40,430
45,580
50,730

For families/households with more
than 8 persons, add $5,150 for each
additional person.
Separate poverty guideline figures for
Alaska and Hawaii reflect Office of
Economic Opportunity administrative
practice beginning in the 1966–1970
period. (Note that the Census Bureau
poverty thresholds—the version of the
poverty measure used for statistical
purposes—have never had separate
figures for Alaska and Hawaii.) The
poverty guidelines are not defined for
Puerto Rico or other outlying
jurisdictions. In cases in which a
Federal program using the poverty
guidelines serves any of those
jurisdictions, the Federal office that
administers the program is generally
responsible for deciding whether to use
the contiguous-states-and-DC guidelines
for those jurisdictions or to follow some
other procedure.
Due to confusing legislative language
dating back to 1972, the poverty
guidelines sometimes have been
mistakenly referred to as the ‘‘OMB’’
(Office of Management and Budget)
poverty guidelines or poverty line. In
fact, OMB has never issued the
guidelines; the guidelines are issued
each year by the Department of Health
and Human Services. The poverty
guidelines may be formally referenced
as ‘‘the poverty guidelines updated

VerDate Sep<11>2014

18:20 Jan 16, 2020

Jkt 250001

periodically in the Federal Register by
the U.S. Department of Health and
Human Services under the authority of
42 U.S.C. 9902(2).’’
Some Federal programs use a
percentage multiple of the guidelines
(for example, 125 percent or 185 percent
of the guidelines), as noted in relevant
authorizing legislation or program
regulations. Non-Federal organizations
that use the poverty guidelines under
their own authority in non-federallyfunded activities also may choose to use
a percentage multiple of the guidelines.
The poverty guidelines do not make a
distinction between farm and non-farm
families, or between aged and non-aged
units. (Only the Census Bureau poverty
thresholds have separate figures for aged
and non-aged one-person and twoperson units.)
This notice does not provide
definitions of such terms as ‘‘income’’ or
‘‘family’’ as there is considerable
variation of these terms among programs
that use the poverty guidelines. The
legislation or regulations governing each
program define these terms and
determine how the program applies the
poverty guidelines. In cases where
legislation or regulations do not
establish these definitions, the entity
that administers or funds the program is
responsible to define such terms as
‘‘income’’ and ‘‘family.’’ Therefore
questions such as net or gross income,
counted or excluded income, or
household size should be directed to the
entity that administers or funds the
program.
Dated: January 14, 2020.
Alex M. Azar II,
Secretary, Department of Health and Human
Services.
[FR Doc. 2020–00858 Filed 1–15–20; 4:15 pm]
BILLING CODE 4150–05–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–0001]

Agency Information Collection
Request; 30-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.

AGENCY:
ACTION:

In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the

SUMMARY:

PO 00000

Frm 00051

Fmt 4703

Sfmt 4703

3061

Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before February 18, 2020.
ADDRESSES: Submit your comments to
[email protected] or via
facsimile to (202) 395–5806.
FOR FURTHER INFORMATION CONTACT:
Sherrette Funn, [email protected]
or (202) 795–7714. When submitting
comments or requesting information,
please include the document identifier
0990–0001–30D and project title for
reference.
Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Information Collection Request Title:
Application for waiver of the two- year
foreign residence requirement of the
Exchange Visitor Program.
OMB No.: 0990–0001.
Abstract: The HHS program deals
with both research and clinical care
waivers. Applicant institutions apply to
this Department to request a waiver on
behalf of research scientists or foreign
medical graduates to work as clinicians
in HHS designated health shortage areas
doing primary care in medical facilities.
The instructions request a copy of Form
G–28 from applicant institutions
represented by legal counsel outside of
the applying institution. United States
Department of Justice Form G–28
ascertains that legal counsel represents
both the applicant organization and the
exchange visitor.
Need and Proposed Use of the
Information: Required as part of the
application process to collect basic
information such as name, address,
family status, sponsor and current visa
information.
Likely Respondents: Research
scientists and research facilities.

SUPPLEMENTARY INFORMATION:

E:\FR\FM\17JAN1.SGM

17JAN1

3062

Federal Register / Vol. 85, No. 12 / Friday, January 17, 2020 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Average
burden per
response
(in hours)

Total burden
hours

Form name

Application Waiver/Supplemental A Research ....................
Application Waiver/Supplemental B Clinical Care ..............

HHS 426 ........
HHS 426 ........

45
35

1
1

10
10

450
350

Total ..............................................................................

........................

........................

........................

........................

800

Terry Clark,
Office of the Secretary, Asst Paperwork
Reduction Act Reports Clearance Officer.
[FR Doc. 2020–00717 Filed 1–16–20; 8:45 am]
BILLING CODE 4150–38–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

lotter on DSKBCFDHB2PROD with NOTICES

Number of
responses per
respondent

Number of
respondents

Type of respondent

Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Clinical Trials for Psychosocial
Interventions.
Date: February 11, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
[email protected].
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Clinical Trials—Pharma/Device.
Date: February 20, 2020.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001

VerDate Sep<11>2014

18:20 Jan 16, 2020

Jkt 250001

Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
[email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)

Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 6D,
MSC9804, Rockville, MD 20852–9804;
Telephone: (301) 496–2644; Facsimile:
(240) 627–3117; Email: prabhuyo@
niaid.nih.gov.
SUPPLEMENTARY INFORMATION:

Dated: January 13, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.

Intellectual Property
• U.S. Patent 9,481,866—issued
November 1, 2016, entitled ‘‘Methods
of Producing T Cell Populations
Enriched for Stable Regulatory TCells’’ [HHS Reference No. E–279–
2011/0–US–02]
• U.S. Divisional Application No.15/
284,840—filed October 4, 2016,
entitled ‘‘Methods of Producing T Cell
Populations Enriched for Stable
Regulatory T-Cells’. [HHS Reference
No. E–279–2011/0–US–03]
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory will be the United States and
the field of use will be limited to:
‘‘Human cell-based therapeutics for the
treatment of Hemophilia A in patients
that have inhibitory Factor VIII
antibodies.’’
The technology is directed to a
method for producing or growing cell
populations that are enriched for stable,
highly suppressive regulatory T cells
(Tregs). Tregs are critical in regulating
immune system processes that maintain
tolerance to self-antigens and prevent
immune mediated diseases. The method
takes a population of cells comprising
stable, regulatory T cells and enriched
for specific CD markers, cultures these
cells in the presence of interleukin-2, an
anti-CD3 antibody, an anti-CD28
antibody, and oligodeoxynucleotides of
specified length having a
phosphorothioate backbone, and yields
the expansion of the initial population
of regulatory T-cells. The expanded
Tregs may then be used for the
treatment of immune-mediated diseases.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.

[FR Doc. 2020–00688 Filed 1–16–20; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Development of Regulatory
T-Cell Therapies for the Treatment of
Hemophilia A (HA)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to TeraImmune,
Inc. (‘‘TeraImmune’’) located in
Rockville, Maryland.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
Property Office on or before February 3,
2020 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Dr. Yogikala Prabhu,
SUMMARY:

PO 00000

Frm 00052

Fmt 4703

Sfmt 4703

E:\FR\FM\17JAN1.SGM

17JAN1